TOP1 and small cell lung carcinoma: We also investigated the potential effects of combining ATR (M4344/VX‐803) and TOP1 (topotecan) inhibitors in triggering immune response signaling and oncogenic signaling pathways in SCLC cells, which could provide a new therapeutic strategy for SCLC.